...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant
【24h】

Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant

机译：用Etonogestrel-释放避孕植入物治疗矫直类内膜异位症

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study aimed to investigate the efficacy of the etonogestrel (ENG)-releasing implant in treating patients with rectovaginal endometriosis. The study was based on the retrospective analysis of a prospectively collected database, including symptomatic women who had ultrasonographic diagnosis of rectovaginal endometriosis. Patients were follow-up at 6, 12 and 24 months from the insertion of the ENG-releasing implant. The intensity of pain symptoms was evaluated using a visual analog scale. The volume of the nodules was estimated by virtual organ computer-aided analysis. The Endometriosis Health Profile (EHP-30) was used to evaluate quality of life. Overall, 43 women were included in the study. The 2-year continuation rate for the ENG-releasing implant was 93.0%. The treatment quickly improved the intensity of non-menstrual pelvic pain, deep dyspareunia, dysmenorrhea, and dyschezia. At 6-month follow-up, there were improvements in all domains of the EHP-30 compared with baseline. Further improvements in the EHP-30 results were observed only in pain sub score at 12-month follow-up and in emotional well-being sub score at 24-month follow-up. At 6-month follow-up the volume of the rectovaginal nodules was significantly lower compared with baseline; a further decrease was observed at 12- and 24-month follow-up. The treatment was well tolerated.
机译：本研究旨在探讨Etonegestrel（Eng）-Releleing植入物治疗矫直类药物异位症患者的疗效。该研究基于对预期收集的数据库的回顾性分析，包括具有外胚胚胎异构症的超声诊断的症状性妇女。患者在插入刀具植入物的6,12和24个月后随访。使用视觉模拟规模评估疼痛症状的强度。虚拟器官计算机辅助分析估计结节的体积。子宫内膜异位症健康概况（EHP-30）用于评估生命的质量。总体而言，43名妇女被纳入该研究。 ENG释放植入物的2年延续率为93.0％。该治疗迅速提高了非月经骨盆疼痛，深呼吸道紊乱，痛经和延迟的强度。在6个月的随访中，与基线相比，EHP-30的所有领域都有改进。 EHP-30结果的进一步改善仅在12个月的跟进和情绪良好的Sub得分中观察到EHP-30结果，在24个月的随访中。在6个月后续随访，与基线相比，Rectovaginal Nodules的体积显着降低;观察到在12-和24个月随访中进一步减少。治疗良好耐受。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号